Hepion Pharmaceuticals Inc (HEPA) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form 8-K - Current report

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Hepion Pharmaceuticals to Present at NASH-TAG 2024

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form 8-K - Current report

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Restructuring program purpose is to preserve capital and optimize clinical development program Management...

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results...

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form EFFECT - Notice of Effectiveness

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...